Sexually Transmitted Diseases (STD) Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments And Services, Consumables, Software), By Application (HIV Testing, HSV Testing, CT/NG Testing, Syphilis Testing, Gonorrhea Testing, Others), By Technology (Immunoassay, Molecular Diagnostics, Other), By Location Of Testing (Laboratory Testing, Point Of Care Testing, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 103.07 Billion
CAGR (2026-2031)	6.61%
Fastest Growing Segment	Instruments and Service
Largest Market	North America
Market Size (2031)	USD 151.33 Billion

Market Overview

The Global Sexually Transmitted Diseases (STD) Diagnostics Market will grow from USD 103.07 Billion in 2025 to USD 151.33 Billion by 2031 at a 6.61% CAGR. Sexually Transmitted Diseases (STD) diagnostics encompass the reagents, consumables, and instrument platforms specifically engineered for the identification of pathogens responsible for infections such as Chlamydia, Gonorrhea, and Syphilis. The market expansion is primarily supported by the escalating global prevalence of these infections and the implementation of government initiatives that promote routine screening to facilitate early intervention and treatment.

According to the American Sexual Health Association, in 2025, surveillance data highlighted that the overall number of reported sexually transmitted infections remained 13% higher compared to the levels recorded a decade prior. Despite this high burden driving demand, the market encounters a significant challenge regarding the social stigma associated with testing, which frequently discourages individuals from seeking necessary diagnostic services and consequently impedes broader market penetration.

Key Market Drivers

Escalating Global Incidence of Sexually Transmitted Infections serves as the foundational catalyst for market growth, necessitating robust testing infrastructure to manage outbreak vectors and prevent long-term complications. The resurgence of bacterial infections, particularly in developed regions, compels healthcare systems to procure higher volumes of molecular and immunoassay-based diagnostic consumables to address the expanding patient burden. According to the UK Health Security Agency, June 2025, in the 'Sexually transmitted infections and screening for chlamydia in England: 2024 report', early-stage syphilis diagnoses reached 9,535 cases in 2024, representing a 2% increase from the previous year and highlighting the persistent upward trajectory of complex infections. This rising prevalence directly correlates with increased laboratory throughput and the procurement of high-throughput analyzers. Furthermore, according to the Centers for Disease Control and Prevention, in 2025, provisional data indicated that more than 2.2 million total cases of chlamydia, gonorrhea, and syphilis were reported in the United States for the 2024 surveillance period, underscoring the sustained high volume of diagnostic demand.

Increasing Consumer Adoption of At-Home and Self-Collection Testing Kits is reshaping the diagnostic landscape by decentralizing patient care and bypassing the traditional barriers of clinical stigma and scheduling logistics. This shift is powered by regulatory approvals of over-the-counter molecular platforms that offer lab-quality accuracy in a private setting, thereby expanding the addressable market to untreated, asymptomatic populations. According to the U.S. Food and Drug Administration, March 2025, in the 'FDA Grants Marketing Authorization of First Home Test for Chlamydia, Gonorrhea and Trichomoniasis' press announcement, the newly authorized Visby Medical Women's Sexual Health Test demonstrated a clinical performance of 97.2% correct identification for positive Chlamydia trachomatis samples during validation. The availability of such high-performance self-tests encourages more frequent screening behaviors among younger demographics, driving revenue growth for manufacturers of direct-to-consumer diagnostic solutions and reducing the operational burden on sexual health clinics.

Download Free Sample Report

Key Market Challenges

Social stigma regarding sexually transmitted diseases serves as a substantial restraint on the global diagnostics market by discouraging individuals from seeking timely screening. This psychological barrier creates a strong reluctance to visit clinics or utilize testing services due to fear of judgment, embarrassment, or privacy concerns. Consequently, a significant segment of the at-risk population avoids necessary testing, which directly reduces the volume of diagnostic tests, reagents, and consumables utilized in clinical settings. This avoidance limits the addressable market size and restricts revenue generation for manufacturers.

The impact of this testing gap is evident when analyzing the disparity between infection estimates and actual diagnostic uptake. According to the World Health Organization, in 2024, more than 1 million sexually transmitted infections were acquired daily worldwide, yet a vast portion of these cases remained undiagnosed. This data highlights that despite the availability of testing platforms, the market cannot fully capitalize on the rising prevalence of infections because social apprehension effectively blocks patient entry into the diagnostic ecosystem.

Key Market Trends

The Transition Towards Multiplex Nucleic Acid Amplification Tests (NAATs) is fundamentally altering clinical workflows by enabling the simultaneous detection of multiple pathogens from a single patient specimen. This shift towards syndromic panel testing addresses the high rates of co-infections, such as chlamydia presenting alongside gonorrhea or trichomoniasis, which single-target assays frequently miss. By consolidating testing into a single run, laboratories can significantly reduce turnaround times and operational costs while ensuring comprehensive diagnosis. This efficiency is driving substantial commercial adoption, as healthcare providers prioritize platforms that offer broader diagnostic coverage. According to Hologic, Inc., November 2024, in the 'Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024' press release, molecular diagnostics revenue increased by 9.4% compared to the prior year, primarily driven by the elevated sales volume of their multiplex assay for the detection of bacterial vaginosis, Candida vaginitis, and Trichomonas vaginalis.

The Implementation of Next-Generation Sequencing for Genomic Surveillance is gaining critical momentum as a response to the escalating threat of antimicrobial resistance in sexually transmitted pathogens. Unlike traditional diagnostics that only confirm infection status, genomic sequencing allows public health bodies to identify specific resistance mutations and track transmission clusters of superbugs, particularly Neisseria gonorrhoeae. This capability is essential for tailoring antibiotic treatment protocols and preserving the efficacy of last-line therapies in the face of evolving bacterial strains. According to the World Health Organization, November 2025, in the 'WHO warns of rising, worrisome levels of drug-resistant gonorrhea' news release, surveillance data indicated that resistance to ceftriaxone and cefixime rose to 5% and 11% respectively between 2022 and 2024, necessitating the urgent deployment of advanced genomic profiling to manage these resistant isolates.

Segmental Insights

The Instruments and Services segment is identified as the fastest-growing category within the Global Sexually Transmitted Diseases Diagnostics Market. This accelerated expansion is primarily driven by the increasing adoption of automated testing platforms in clinical laboratories to manage higher sample volumes. Continuous product approvals by authorities such as the U.S. FDA encourage healthcare facilities to procure updated diagnostic hardware. Additionally, the essential requirement for ongoing technical support and maintenance agreements to ensure device reliability sustains demand for the services component of this segment.

Regional Insights

North America maintains a dominant share of the global sexually transmitted diseases diagnostics market, supported by robust healthcare infrastructure and proactive government initiatives. High public awareness regarding sexual health and favorable reimbursement coverage encourage consistent patient screening throughout the region. The market also benefits from the strong presence of key industry players in the United States, which ensures the ready availability of diagnostic tests. Furthermore, the U.S. Food and Drug Administration facilitates market stability by providing clear regulatory pathways for the approval of new diagnostic assays, collectively underpinning the region's leading position.

Recent Developments

• In March 2025, Visby Medical received FDA marketing authorization for its Women’s Sexual Health Test, marking the first approval of an at-home, over-the-counter diagnostic capable of detecting chlamydia, gonorrhea, and trichomoniasis. The single-use, instrument-free polymerase chain reaction (PCR) device was cleared for use by women with or without symptoms and was engineered to deliver laboratory-quality results in under 30 minutes. This product launch addressed critical barriers to testing such as convenience and privacy, and it highlighted the industry's shift towards sophisticated, patient-centric solutions that expand access to molecular diagnostics outside of traditional clinical laboratories.
• In January 2025, Roche announced that it had obtained FDA 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its cobas liat sexually transmitted infection (STI) multiplex assay panels. These molecular diagnostic tests were designed to detect and differentiate Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium within 20 minutes using a single patient sample. The introduction of these assays on the portable cobas liat system significantly expanded the company's presence in the decentralized Global Sexually Transmitted Diseases (STD) Diagnostics Market, allowing healthcare providers in urgent care and community settings to make immediate, informed treatment decisions during a single patient visit.
• In August 2024, NOWDiagnostics received marketing authorization from the FDA for the First To Know Syphilis Test, establishing a major breakthrough in the consumer diagnostics sector. This product became the first over-the-counter test for syphilis available for at-home use in the United States, directly addressing the need for accessible screening options amidst rising infection rates. The rapid membrane immunoassay was engineered to detect Treponema pallidum antibodies from a single drop of blood obtained via a fingerstick, providing results in approximately 15 minutes. This development enabled individuals to perform preliminary screening privately, facilitating earlier diagnosis and subsequent medical treatment.
• In February 2024, Hologic, Inc. announced that it had received clearance from the U.S. Food and Drug Administration (FDA) for its Genius Digital Diagnostics System featuring the Genius Cervical AI algorithm. This launch represented a significant technological advancement in the Global Sexually Transmitted Diseases (STD) Diagnostics Market as the first FDA-cleared digital cytology platform to integrate deep-learning-based artificial intelligence with advanced volumetric imaging. The system was designed to assist cytologists and pathologists in identifying pre-cancerous lesions and cervical cancer cells more accurately, working in conjunction with the company's existing ThinPrep Pap test and Aptima HPV Assay to enhance cervical cancer screening workflows.

Key Market Players

• Becton Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• bioMérieux S.A.
• Abbott Laboratories Inc.
• Danaher Corporation
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• DiaSorin S.p.A
• Bio-Rad Laboratories, Inc.

By Product	By Application	By Technology	By Location Of Testing	By Region
Instruments And Services Consumables Software	HIV Testing HSV Testing CT/NG Testing Syphilis Testing Gonorrhea Testing Others	Immunoassay Molecular Diagnostics Other	Laboratory Testing Point Of Care Testing Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Sexually Transmitted Diseases (STD) Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Sexually Transmitted Diseases (STD) Diagnostics Market, By Product:

• Instruments And Services
• Consumables
• Software

• Sexually Transmitted Diseases (STD) Diagnostics Market, By Application:

• HIV Testing
• HSV Testing
• CT/NG Testing
• Syphilis Testing
• Gonorrhea Testing
• Others

• Sexually Transmitted Diseases (STD) Diagnostics Market, By Technology:

• Immunoassay
• Molecular Diagnostics
• Other

• Sexually Transmitted Diseases (STD) Diagnostics Market, By Location Of Testing:

• Laboratory Testing
• Point Of Care Testing
• Others

• Sexually Transmitted Diseases (STD) Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE